dc.contributor.author |
Domfeh, S.A. |
|
dc.contributor.author |
Narkwa, P.W. |
|
dc.contributor.author |
Quaye, O. |
|
dc.contributor.author |
Kusi, K.A. |
|
dc.contributor.author |
Awandare, G.A. |
|
dc.contributor.author |
Ansah, C. |
|
dc.contributor.author |
Salam, A. |
|
dc.contributor.author |
Mutocheluh, M. |
|
dc.date.accessioned |
2021-09-22T16:32:07Z |
|
dc.date.available |
2021-09-22T16:32:07Z |
|
dc.date.issued |
2021 |
|
dc.identifier.other |
https://doi.org/10.1186/s12906-021-03326-x |
|
dc.identifier.uri |
http://ugspace.ug.edu.gh/handle/123456789/36750 |
|
dc.description.abstract |
Background: Diverse signalling pathways are involved in carcinogenesis and one of such pathways implicated in
many cancers is the interleukin 6/signal transducer and activator of transcription 3 (IL-6/STAT3) signalling pathway.
Therefore, inhibition of this pathway is targeted as an anti-cancer intervention. This study aimed to establish the
effect of cryptolepine, which is the main bioactive alkaloid in the medicinal plant Cryptolepis sanguinolenta, on the
IL-6/STAT3 signalling pathway.
Methods: First, the effect of cryptolepine on the IL-6/STAT3 pathway in human hepatoma cells (HepG2 cells) was
screened using the Cignal Finder Multi-Pathway Reporter Array. Next, to confirm the effect of cryptolepine on the
IL-6/STAT3 signalling pathway, the pathway was activated using 200 ng/mL IL-6 in the presence of 0.5–2 μM
cryptolepine. The levels of total STAT3, p-STAT3 and IL-23 were assessed by ELISA.
Results: Cryptolepine downregulated 12 signalling pathways including the IL-6/STAT3 signalling pathway and
upregulated 17 signalling pathways. Cryptolepine, in the presence of IL-6, decreased the levels of p-STAT3 and IL-23
in a dose-dependent fashion.
Conclusion: Our results demonstrated that cryptolepine inhibits the IL-6/STAT3 signalling pathway, and therefore
cryptolepine-based remedies such as Cryptolepis sanguinolenta could potentially be used as an effective
immunotherapeutic agent for hepatocellular carcinoma and other cancers |
en_US |
dc.description.sponsorship |
This study was supported by a Wellcome/African Academy of Sciences
Developing Excellence in Leadership Training and Science (DELTAS) grant
(DEL-15-007 and 107755/Z/15/Z: Awandare). Additional support came from the Kwame Nkrumah University of Science and Technology Research Fund
(KReF to Mohamed Mutocheluh) |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
BMC Complementary Medicine and Therapies |
en_US |
dc.subject |
Cryptolepine |
en_US |
dc.subject |
IL-6/STAT3 |
en_US |
dc.subject |
Carcinogenesis |
en_US |
dc.subject |
Hepatoma |
en_US |
dc.subject |
Anti-cancer |
en_US |
dc.title |
Cryptolepine inhibits hepatocellular carcinoma growth through inhibiting interleukin-6/STAT3 signalling |
en_US |
dc.type |
Article |
en_US |